Ennature Bio Pharma Limited Lists on NSE and BSE: Biopharma Division Reports Rs 246 Crore in FY26 Revenue

Ennature Bio Pharma Limited (ENNATURE) made a significant milestone on November 4, 2026, by listing on the National Stock Exchange of India (NSE) and BSE Limited. This move brings the company’s integrated natural ingredients business to the listed market, marking a new phase in its growth strategy. The biopharma division reported net revenue of Rs 246 crore, EBITDA of Rs 29 crore, and a gross margin of 40.1% in FY26, with branded nutraceuticals as a key growth driver.

Diverse Business Segments

The company operates three complementary businesses: plant-based pharmaceutical ingredients, biopolymers, and nutraceuticals. The API business, which accounts for 67% of sales, includes thiocolchicoside, colchicine, nicotine, and vinpocetine. The biopolymer segment, contributing 16% of sales, focuses on guar gum and specialty gums used across various industries. The nutraceutical segment, currently making up 17% of sales, is moving towards branded ingredients designed for specific market segments.

Growth Strategy and Expansion Plans

Ennature plans to introduce one new API annually, expand its presence in regulated markets, and strengthen its nicotine replacement therapy portfolio. The company’s biopolymer operations aim to develop specialized derivatives, expand dietary fiber applications, and increase the contribution of higher-value products. The nutraceutical segment plans to expand its branded portfolio to six to eight ingredients, strengthen distribution across the US, Europe, and Asia, and deepen relationships with leading nutraceutical customers.

As a result, Ennature’s growth strategy combines the expansion of its established API portfolio and higher-value biopolymer products with greater investment in branded nutraceuticals. Its listing on NSE and BSE marks a new phase for the business as it seeks to build on its pharmaceutical, research and development, and manufacturing expertise to expand its presence in the global natural ingredients market.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Ennature Bio Pharma Limited

Ennature Bio Pharma Limited. Here’s a quick read on where the business and the stock stand today.

Symbol ENNATURE not found in TradeAlone database.